APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-based Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global RNA-based Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchRNA-based Biopharmaceuticals Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-based Biopharmaceuticals Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal RNA-based Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-based Biopharmaceuticals Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-based Biopharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global RNA-based Biopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of RNA-based Biopharmaceuticals include Roche, Pfizer, Tekmira, Silenseed, Silence Therapeutics, Senesco, Sanofi-Aventis, RXi and Quark, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global RNA-based Biopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA-based Biopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA-based Biopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the RNA-based Biopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

RNA-based Biopharmaceuticals Segment by Company

Roche

Pfizer

Tekmira

Silenseed

Silence Therapeutics

Senesco

Sanofi-Aventis

RXi

Quark

Gradalis

Dicerna

Calimmune Inc

Benitec Biopharma

Arrowhead Pharmaceuticals

Alnylam Pharmaceuticals

Abbott Laboratories

RNA-based Biopharmaceuticals Segment by Type

Therapeutics

Vaccines

RNA-based Biopharmaceuticals Segment by Application

Cancer

Tuberculosis

Diabetes

Cardiovascular Diseases

Others

RNA-based Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-based Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-based Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-based Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RNA-based Biopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of RNA-based Biopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of RNA-based Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of RNA-based Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. RNA-based Biopharmaceuticals Industry Trends Table 2. RNA-based Biopharmaceuticals Industry Drivers Table 3. RNA-based Biopharmaceuticals Industry Opportunities and Challenges Table 4. RNA-based Biopharmaceuticals Industry Restraints Table 5. Global RNA-based Biopharmaceuticals Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global RNA-based Biopharmaceuticals Revenue Market Share by Manufacturers (2021-2026) Table 7. Global RNA-based Biopharmaceuticals Sales by Manufacturers (k units) & (2021-2026) Table 8. Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers Table 9. Global RNA-based Biopharmaceuticals Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global RNA-based Biopharmaceuticals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global RNA-based Biopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global RNA-based Biopharmaceuticals Manufacturers, Product Type & Application Table 13. Global RNA-based Biopharmaceuticals Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global RNA-based Biopharmaceuticals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Therapeutics Table 17. Major Manufacturers of Vaccines Table 18. Global RNA-based Biopharmaceuticals Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 20. Global RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 21. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2026) Table 22. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2027-2032) Table 23. Global RNA-based Biopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (k units) Table 25. Global RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (k units) Table 26. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 27. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Cancer Table 29. Major Manufacturers of Tuberculosis Table 30. Major Manufacturers of Diabetes Table 31. Major Manufacturers of Cardiovascular Diseases Table 32. Major Manufacturers of Others Table 33. Global RNA-based Biopharmaceuticals Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 35. Global RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 36. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2026) Table 37. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2027-2032) Table 38. Global RNA-based Biopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (k units) Table 40. Global RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (k units) Table 41. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 42. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 43. Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global RNA-based Biopharmaceuticals Sales by Region (2021-2026) & (k units) Table 45. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2026) Table 46. Global RNA-based Biopharmaceuticals Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global RNA-based Biopharmaceuticals Sales Forecasted Market Share by Region (2027-2032) Table 48. North America RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 50. North America RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 51. Europe RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 53. Europe RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 60. Global RNA-based Biopharmaceuticals Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global RNA-based Biopharmaceuticals Revenue by Region (2021-2026) & (US$ Million) Table 62. Global RNA-based Biopharmaceuticals Revenue by Region (2027-2032) & (US$ Million) Table 63. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2026) Table 64. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2027-2032) Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Roche RNA-based Biopharmaceuticals Product Portfolio Table 69. Roche Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer RNA-based Biopharmaceuticals Product Portfolio Table 74. Pfizer Recent Development Table 75. Tekmira Company Information Table 76. Tekmira Business Overview Table 77. Tekmira RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Tekmira RNA-based Biopharmaceuticals Product Portfolio Table 79. Tekmira Recent Development Table 80. Silenseed Company Information Table 81. Silenseed Business Overview Table 82. Silenseed RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Silenseed RNA-based Biopharmaceuticals Product Portfolio Table 84. Silenseed Recent Development Table 85. Silence Therapeutics Company Information Table 86. Silence Therapeutics Business Overview Table 87. Silence Therapeutics RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio Table 89. Silence Therapeutics Recent Development Table 90. Senesco Company Information Table 91. Senesco Business Overview Table 92. Senesco RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Senesco RNA-based Biopharmaceuticals Product Portfolio Table 94. Senesco Recent Development Table 95. Sanofi-Aventis Company Information Table 96. Sanofi-Aventis Business Overview Table 97. Sanofi-Aventis RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio Table 99. Sanofi-Aventis Recent Development Table 100. RXi Company Information Table 101. RXi Business Overview Table 102. RXi RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. RXi RNA-based Biopharmaceuticals Product Portfolio Table 104. RXi Recent Development Table 105. Quark Company Information Table 106. Quark Business Overview Table 107. Quark RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Quark RNA-based Biopharmaceuticals Product Portfolio Table 109. Quark Recent Development Table 110. Gradalis Company Information Table 111. Gradalis Business Overview Table 112. Gradalis RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Gradalis RNA-based Biopharmaceuticals Product Portfolio Table 114. Gradalis Recent Development Table 115. Dicerna Company Information Table 116. Dicerna Business Overview Table 117. Dicerna RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Dicerna RNA-based Biopharmaceuticals Product Portfolio Table 119. Dicerna Recent Development Table 120. Calimmune Inc Company Information Table 121. Calimmune Inc Business Overview Table 122. Calimmune Inc RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio Table 124. Calimmune Inc Recent Development Table 125. Benitec Biopharma Company Information Table 126. Benitec Biopharma Business Overview Table 127. Benitec Biopharma RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio Table 129. Benitec Biopharma Recent Development Table 130. Arrowhead Pharmaceuticals Company Information Table 131. Arrowhead Pharmaceuticals Business Overview Table 132. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 134. Arrowhead Pharmaceuticals Recent Development Table 135. Alnylam Pharmaceuticals Company Information Table 136. Alnylam Pharmaceuticals Business Overview Table 137. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 139. Alnylam Pharmaceuticals Recent Development Table 140. Abbott Laboratories Company Information Table 141. Abbott Laboratories Business Overview Table 142. Abbott Laboratories RNA-based Biopharmaceuticals Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio Table 144. Abbott Laboratories Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. RNA-based Biopharmaceuticals Distributors List Table 148. RNA-based Biopharmaceuticals Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. RNA-based Biopharmaceuticals Product Image Figure 2. Global RNA-based Biopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-based Biopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global RNA-based Biopharmaceuticals Sales (2021-2032) & (k units) Figure 5. Global RNA-based Biopharmaceuticals Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 RNA-based Biopharmaceuticals Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Therapeutics Image Figure 9. Vaccines Image Figure 10. Global RNA-based Biopharmaceuticals Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global RNA-based Biopharmaceuticals Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032) Figure 13. Global RNA-based Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global RNA-based Biopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 16. Cancer Image Figure 17. Tuberculosis Image Figure 18. Diabetes Image Figure 19. Cardiovascular Diseases Image Figure 20. Others Image Figure 21. Global RNA-based Biopharmaceuticals Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global RNA-based Biopharmaceuticals Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032) Figure 24. Global RNA-based Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global RNA-based Biopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 27. North America RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 29. U.S. RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 34. Germany RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 35. France RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 41. China RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 45. India RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 49. Brazil RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile RNA-based Biopharmaceuticals Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global RNA-based Biopharmaceuticals Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global RNA-based Biopharmaceuticals Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 60. North America RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 62. Europe RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. RNA-based Biopharmaceuticals Value Chain Figure 68. Manufacturing Cost Structure Figure 69. RNA-based Biopharmaceuticals Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutics
  • Vaccines
Applications
  • Cancer
  • Tuberculosis
  • Diabetes
  • Cardiovascular Diseases
  • Others
Companies covered
  • Roche
  • Pfizer
  • Tekmira
  • Silenseed
  • Silence Therapeutics
  • Senesco
  • Sanofi-Aventis
  • RXi
  • Quark
  • Gradalis
  • Dicerna
  • Calimmune Inc
  • Benitec Biopharma
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global RNA-based Biopharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global RNA-based Biopharmaceuticals Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global RNA-based Biopharmaceuticals Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global RNA-based Biopharmaceuticals Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global RNA-based Biopharmaceuticals Market Dynamics
  1. 2.1 RNA-based Biopharmaceuticals Industry Trends
  2. 2.2 RNA-based Biopharmaceuticals Industry Drivers
  3. 2.3 RNA-based Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 RNA-based Biopharmaceuticals Industry Restraints
3 RNA-based Biopharmaceuticals Market by Manufacturers
  1. 3.1 Global RNA-based Biopharmaceuticals Revenue by Manufacturers (2021-2026)
  2. 3.2 Global RNA-based Biopharmaceuticals Sales by Manufacturers (2021-2026)
  3. 3.3 Global RNA-based Biopharmaceuticals Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global RNA-based Biopharmaceuticals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global RNA-based Biopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global RNA-based Biopharmaceuticals Manufacturers, Product Type & Application
  7. 3.7 Global RNA-based Biopharmaceuticals Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global RNA-based Biopharmaceuticals Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 RNA-based Biopharmaceuticals Players Market Share by Revenue in 2025
  11. 3.8.3 2025 RNA-based Biopharmaceuticals Tier 1, Tier 2, and Tier 3
4 RNA-based Biopharmaceuticals Market by Type
  1. 4.1 RNA-based Biopharmaceuticals Type Introduction
  2. 4.1.1 Therapeutics
  3. 4.1.2 Vaccines
  4. 4.2 Global RNA-based Biopharmaceuticals Sales by Type
  5. 4.2.1 Global RNA-based Biopharmaceuticals Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  7. 4.2.3 Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032)
  8. 4.3 Global RNA-based Biopharmaceuticals Revenue by Type
  9. 4.3.1 Global RNA-based Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  11. 4.3.3 Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032)
5 RNA-based Biopharmaceuticals Market by Application
  1. 5.1 RNA-based Biopharmaceuticals Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Tuberculosis
  4. 5.1.3 Diabetes
  5. 5.1.4 Cardiovascular Diseases
  6. 5.1.5 Others
  7. 5.2 Global RNA-based Biopharmaceuticals Sales by Application
  8. 5.2.1 Global RNA-based Biopharmaceuticals Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  10. 5.2.3 Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032)
  11. 5.3 Global RNA-based Biopharmaceuticals Revenue by Application
  12. 5.3.1 Global RNA-based Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  14. 5.3.3 Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032)
6 Global RNA-based Biopharmaceuticals Sales by Region
  1. 6.1 Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA-based Biopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global RNA-based Biopharmaceuticals Sales by Region (2021-2026)
  4. 6.2.2 Global RNA-based Biopharmaceuticals Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa RNA-based Biopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global RNA-based Biopharmaceuticals Revenue by Region
  1. 7.1 Global RNA-based Biopharmaceuticals Revenue by Region
  2. 7.1.1 Global RNA-based Biopharmaceuticals Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global RNA-based Biopharmaceuticals Revenue by Region (2021-2026)
  4. 7.1.3 Global RNA-based Biopharmaceuticals Revenue by Region (2027-2032)
  5. 7.1.4 Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America RNA-based Biopharmaceuticals Revenue (2021-2032)
  8. 7.2.2 North America RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe RNA-based Biopharmaceuticals Revenue (2021-2032)
  11. 7.3.2 Europe RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific RNA-based Biopharmaceuticals Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa RNA-based Biopharmaceuticals Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa RNA-based Biopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche RNA-based Biopharmaceuticals Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer RNA-based Biopharmaceuticals Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Tekmira
  14. 8.3.1 Tekmira Company Information
  15. 8.3.2 Tekmira Business Overview
  16. 8.3.3 Tekmira RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tekmira RNA-based Biopharmaceuticals Product Portfolio
  18. 8.3.5 Tekmira Recent Developments
  19. 8.4 Silenseed
  20. 8.4.1 Silenseed Company Information
  21. 8.4.2 Silenseed Business Overview
  22. 8.4.3 Silenseed RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Silenseed RNA-based Biopharmaceuticals Product Portfolio
  24. 8.4.5 Silenseed Recent Developments
  25. 8.5 Silence Therapeutics
  26. 8.5.1 Silence Therapeutics Company Information
  27. 8.5.2 Silence Therapeutics Business Overview
  28. 8.5.3 Silence Therapeutics RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio
  30. 8.5.5 Silence Therapeutics Recent Developments
  31. 8.6 Senesco
  32. 8.6.1 Senesco Company Information
  33. 8.6.2 Senesco Business Overview
  34. 8.6.3 Senesco RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Senesco RNA-based Biopharmaceuticals Product Portfolio
  36. 8.6.5 Senesco Recent Developments
  37. 8.7 Sanofi-Aventis
  38. 8.7.1 Sanofi-Aventis Company Information
  39. 8.7.2 Sanofi-Aventis Business Overview
  40. 8.7.3 Sanofi-Aventis RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio
  42. 8.7.5 Sanofi-Aventis Recent Developments
  43. 8.8 RXi
  44. 8.8.1 RXi Company Information
  45. 8.8.2 RXi Business Overview
  46. 8.8.3 RXi RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 RXi RNA-based Biopharmaceuticals Product Portfolio
  48. 8.8.5 RXi Recent Developments
  49. 8.9 Quark
  50. 8.9.1 Quark Company Information
  51. 8.9.2 Quark Business Overview
  52. 8.9.3 Quark RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Quark RNA-based Biopharmaceuticals Product Portfolio
  54. 8.9.5 Quark Recent Developments
  55. 8.10 Gradalis
  56. 8.10.1 Gradalis Company Information
  57. 8.10.2 Gradalis Business Overview
  58. 8.10.3 Gradalis RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gradalis RNA-based Biopharmaceuticals Product Portfolio
  60. 8.10.5 Gradalis Recent Developments
  61. 8.11 Dicerna
  62. 8.11.1 Dicerna Company Information
  63. 8.11.2 Dicerna Business Overview
  64. 8.11.3 Dicerna RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dicerna RNA-based Biopharmaceuticals Product Portfolio
  66. 8.11.5 Dicerna Recent Developments
  67. 8.12 Calimmune Inc
  68. 8.12.1 Calimmune Inc Company Information
  69. 8.12.2 Calimmune Inc Business Overview
  70. 8.12.3 Calimmune Inc RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio
  72. 8.12.5 Calimmune Inc Recent Developments
  73. 8.13 Benitec Biopharma
  74. 8.13.1 Benitec Biopharma Company Information
  75. 8.13.2 Benitec Biopharma Business Overview
  76. 8.13.3 Benitec Biopharma RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio
  78. 8.13.5 Benitec Biopharma Recent Developments
  79. 8.14 Arrowhead Pharmaceuticals
  80. 8.14.1 Arrowhead Pharmaceuticals Company Information
  81. 8.14.2 Arrowhead Pharmaceuticals Business Overview
  82. 8.14.3 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  84. 8.14.5 Arrowhead Pharmaceuticals Recent Developments
  85. 8.15 Alnylam Pharmaceuticals
  86. 8.15.1 Alnylam Pharmaceuticals Company Information
  87. 8.15.2 Alnylam Pharmaceuticals Business Overview
  88. 8.15.3 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  90. 8.15.5 Alnylam Pharmaceuticals Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories RNA-based Biopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 RNA-based Biopharmaceuticals Value Chain Analysis
  2. 9.1.1 RNA-based Biopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 RNA-based Biopharmaceuticals Production Mode & Process
  6. 9.2 RNA-based Biopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 RNA-based Biopharmaceuticals Distributors
  9. 9.2.3 RNA-based Biopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst